There are ongoing clinical trials in several cancers, including PDAC, for drugs targeting the ectonucleotidase CD73 (NCT03454451, NCT03454451) and adenosine receptor 2 A (NCT03454451) in combination with PD-1 checkpoint inhibitors and/or chemotherapy. This evidence concerns the gene NT5E and cancer.